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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated vascu-
litis (AAV) is characterized by necrotizing vasculitis in capillaries, 
arterioles, and venules and few apparent immune complex de-
posits in perivascular tissues. Based on clinical and pathological 
features, AAV comprises three subtypes: microscopic polyangi-
itis (MPA), granulomatosis with polyangiitis (GPA) and eosino-
philic granulomatosis with polyangiitis (EGPA).1,2 
The European League Against Rheumatism (EULAR)/Euro-
pean Renal Association-European Dialysis and Transplant As-
sociation (ERA-EDTA) recommendations for the management 
of AAV currently recommend a combination of low-dose glu-
cocorticoid and either azathioprine (AZA), rituximab (RTX), 
methotrexate (MTX) or mycophenolate mofetil (MMF) for re-
mission maintenance therapy.3 Among the four recommend-
ed immunosuppressive drugs, AZA is the most widely used 
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for remission maintenance of MPA and GPA because it has the 
highest level of evidence (1B) and grade of recommendation 
(A). However, the level of evidence and grade of recommenda-
tion for AZA in remission maintenance therapy for EGPA are 3 
and C, respectively, which are lower than those for MPA and 
GPA.3 
The recommendation strength for RTX, MTX, and MMF in 
remission maintenance therapy ranges from 53% to 59%, far less 
than the value of 94% for AZA.3 Nevertheless, in actual clinical 
situations, there may be cases in which it is difficult to prescribe 
AZA, such as in patients with elevated liver enzyme levels or 
leukocytopenia.4,5 In these cases, one of the remaining three 
drugs should be selected. However, RTX in remission mainte-
nance therapy for MPA and GPA is not covered by the Korean 
National Health Insurance despite its proven efficacy.6 In ad-
dition, MTX is not sufficient to maintain the remission of MPA 
and GPA with major organ involvement.7 Therefore, MMF may 
emerge as an alternative remission maintenance therapy for 
MPA and GPA in cases in which AZA is contraindicated. How-
ever, the efficacy of MMF is not as high as expected: a clinical 
trial conducted by the European Vasculitis Study Group dem-
onstrated a significantly higher relapse-preventive potential for 
AZA than MMF in patients with MPA and GPA.8 
Therefore, the present study was undertaken to re-evaluate 
and compare the efficacy of MMF and AZA in remission main-




The algorithm of inclusion and exclusion of patients is described 
in Fig. 1. The medical records of 179 patients with MPA and 
GPA enrolled in the Severance Hospital ANCA-associated 
VasculitidEs (SHAVE) cohort were retrospectively reviewed. 
The SHAVE cohort is a prospective observational cohort of pa-
tients with MPA, GPA, and EGPA established in November 
2016. All patients were first classified to have MPA or GPA ac-
cording to the 2007 European Medicines Agency algorithm 
for AAV and polyarteritis nodosa and the 2012 revised Chapel 
Hill Consensus Conference Nomenclature of Vasculitides.1,2 
The patients had never received remission induction or main-
tenance therapies for AAV and had no medical conditions, such 
as malignancies, infectious diseases, or hematological disor-
ders, at diagnosis. They were followed up for ≥3 months from 
their AAV diagnosis. Of 179 patients, 85 were excluded because 
they did not receive cyclophosphamide (CYC) in remission in-
duction therapy. Of the 94 patients taking CYC, 20 were exclud-
ed owing to the administration of only glucocorticoid without 
the administration of any immunosuppressive drug. Further-
more, five patients were excluded owing to the use of tacrolim-
us or MTX instead of AZA or MMF in remission maintenance 
therapy along with glucocorticoid therapy. Finally, this study 
included 69 patients who received CYC for remission induc-
tion therapy and AZA or MMF for remission maintenance ther-
apy along with glucocorticoid. For remission induction therapy, 
all patients received glucocorticoid pulse therapy (1 g for 3 days 
or 500 mg for 5 days), followed by high-dose prednisolone (1 
mg/kg/day) for 4 weeks and tapered to 5 to 10 mg per day over 
3 months. CYC was administered as intravenous pulse therapy 
[15 mg/kg - maximum pulse dose 1.2 g, dose adjusted by esti-
mated glomerular filtration rate (eGFR) and age] with six cycles 
of infusion for 3 to 6 months.9 AZA was orally administered with 
a target dose of 2 mg/kg/day, and MMF was administered with 
a target dose of 2–3 g/day depending on the patient’s condition 
during the maintenance therapy. This study was approved by 
the Institutional Review Board of Severance Hospital (4-2017-
0673), which waived the need for written informed consent 
from the patients owing to the retrospective nature of the study.
Clinical and laboratory data at diagnosis
Data on age, sex, body mass index (BMI), and smoking history 
(or current smoker) were collected as demographic data. AAV 
subtypes and ANCA positivity were reviewed, and the pres-
Fig. 1. Algorithm for the inclusion and exclusion of patients MPA and GPA. MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; CYC, 
cyclophosphamide; AZA, azathioprine; MMF, mycophenolate mofetil; TAC, tacrolimus; MTX, methotrexate. 
179 patients with MPA and GPA
Patients not taking CYC as remission-induction therapy (n=85)
As remission-maintenance therapy
   1) Patients taking no AZA, MMF, TAC or MTX (n=20)
   2) Patients taking MTX without AZA or MMF (n=3)
   3) Patients taking TAC without AZA or MMF (n=2) 
All 69 patients with MPA and GPA took prednisolone
94 patients with MPA and GPA taking CYC 
as remission-induction therapy
69 patients with MPA and GPA taking AZA or MMF 
as remission-maintenance therapy
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ence of clinical manifestations according to nine items of Bir-
mingham Vasculitis Activity Score (BVAS) was recorded. BVAS 
and five-factor score (FFS) were also assessed as AAV-specific 
indices. Chronic kidney disease (CKD) (stage 3–5), diabetes 
mellitus (DM), hypertension (HTN), and dyslipidemia were 
identified, and erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) levels were evaluated.
Poor prognosis and follow-up period
All-cause mortality, relapse, end-stage renal disease (ESRD), 
cerebrovascular accident (CVA), and cardiovascular disease 
(CVD) during follow-up were defined and evaluated as poor 
outcomes of MPA and GPA. The follow-up duration was de-
fined as the period between the date of AAV diagnosis and the 
date of the last visit for surviving patients. For deceased pa-
tients, the follow-up duration based on all-cause mortality was 
defined as the period between the initial AAV diagnosis and 
the time of death. For patients with poor outcomes, the follow-
up duration based on each poor outcome was defined as the 
period starting from AAV diagnosis until the occurrence of 
each poor outcome.
Medications administered during follow-up
During the follow-up period, the numbers of patients taking 
AZA only, those taking MMF only, and those taking MMF af-
ter AZA were counted. Since CYC was administered to all pa-
tients for remission induction therapy and glucocorticoid was 
also provided to all patients in combination with AZA or MMF 
in remission maintenance therapy, the subgroups were sim-
ply labelled AZA only, MMF after AZA, and MMF only.
Higher and lower BVAS at diagnosis
When patients were divided into two groups based on a BVAS 
of 11, which is the upper limit of the lowest tertile of BVAS, 47 
and 22 patients, respectively, were assigned to the higher (BVAS 
>11) and the lower (BVAS ≤11) BVAS groups.
Statistical analyses
All statistical analyses were conducted using IBM SPSS Statis-
tics for Windows, version 25.0 (IBM Corp., Armonk, NY, USA). 
Continuous variables were expressed as medians (interquar-
tile range) and categorical variables as numbers (%). Significant 
differences in categorical variables between the two groups 
were analyzed using the chi-square and Fisher’s exact tests. Sig-
nificant differences in continuous variables between the two 
groups were compared using the Mann Whitney U test. Com-
parison of the cumulative poor outcome-free survival rates be-
tween the two groups was performed by Kaplan-Meier surviv-
al analysis with log-rank test. A multivariable Cox hazards 
model including variables with statistical significance in a uni-
variable Cox hazards model was used to obtain hazard ratios 




The median age of patients was 59.0 years, and 42 were female. 
The median BMI was 22.3 kg/m2, and only three patients were 
ex-smokers. Of the 69 patients, 54 were diagnosed with MPA, 
and 15 were diagnosed with GPA. ANCA was detected in 62 
patients. The most frequently observed clinical manifestation 
was renal manifestation (76.8%), followed by pulmonary 
(53.6%) and general (50.7%) manifestations. The median 
BVAS, FFS, ESR, and CRP levels were 14.0, 1.0, 76.0 mm/h, and 
19.1 mg/L, respectively. Thirty patients had CKD (stage 3–5), 
and 24 had HTN (Table 1). 
Characteristics during follow-up
Of the 69 patients, 11 (15.9%) died during the median follow-
up period of 32.9 months. Relapse, ESRD, CVA, and CVD were 
observed in 42.0%, 26.1%, 10.1%, and 7.2% of the study popu-
lation, respectively. In remission maintenance therapy, AZA 
was administered to 58 patients, whereas MMF was adminis-
tered to 24 patients, of which 11 were maintained on MMF only 
and 13 received MMF after AZA (Table 1).
Comparison variables at diagnosis
Patients taking AZA were older and had higher BMI than those 
taking MMF (64 years vs. 54 years and 22.7 kg/m2 vs. 21.2 kg/m2, 
respectively). Among the clinical manifestations, patients tak-
ing AZA exhibited a significantly higher frequency of nervous 
systemic manifestations than those taking MMF (31.1% vs. 
4.2%). No other significant differences in clinical features at 
diagnosis were observed between the two groups (Table 1). 
Comparison variables during follow-up
In terms of poor outcomes of MPA and GPA, patients taking 
MMF exhibited significantly higher frequencies of relapse 
(62.5% vs. 31.1%) and ESRD occurrence (45.8% vs. 15.6%) than 
those taking AZA during follow-up. In addition, patients tak-
ing MMF had longer follow-up periods based on all-cause mor-
tality and CVD, but no significant differences in the frequencies 
of all-cause mortality, CVA, and CVD were observed between 
the two groups (Table 1). 
Comparison of cumulative poor outcome-free survival 
rates
Among the five poor outcomes of MPA and GPA, patients taking 
MMF only or MMF after AZA tended to show lower cumulative 
relapse-free (p=0.117) and ESRD-free (p=0.059) rates during fol-
low-up, compared to those in patients taking AZA only. How-
ever, the difference was not statistically significant (Fig. 2). 
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Table 1. Characteristics and Comparison of Variables at Diagnosis and During Follow-Up in Patients with MPA and GPA
Variables All patients (n=69) AZA (n=45) MMF (n=24) p value
At the time of diagnosis 
Demographic data
Age (yr) 59.0 (18.5) 64.0 (16.5) 54.0 (24.8) 0.022
Female sex 42 (60.9) 23 (51.1) 19 (79.2) 0.037
Body mass index (kg/m2) 22.3 (3.6) 22.7 (3.6) 21.2 (3.8) 0.036
Smoking history (ex-smoker) 3 (4.3) 3 (6.7) 0 (0) 0.547
AAV subtypes 0.550
MPA 54 (78.3) 34 (75.6) 20 (83.3)
GPA 15 (21.7) 11 (24.4) 4 (16.7)
ANCA positivity
MPO-ANCA (or P-ANCA) positive 53 (76.8) 33 (73.3) 20 (83.3) 0.390
PR3-ANCA (or C-ANCA) positive 10 (14.5) 7 (15.6) 3 (12.5) 1.000
Both ANCA positive 1 (1.4) 0 (0) 1 (4.2) 0.348
ANCA negative 7 (10.1) 5 (11.1) 2(8.3) 1.000
Clinical features based on BVAS
General manifestations 35 (50.7) 24 (53.3) 11 (45.8) 0.553
Cutaneous manifestations 10 (14.5) 8 (17.8) 2 (8.3) 0.475
Mucous and ocular manifestations 3 (4.3) 1 (2.2) 2 (8.3) 0.276
Otorhinolaryngologic manifestations 21 (30.4) 13 (28.9) 8 (33.3) 0.702
Pulmonary manifestations 37 (53.6) 22 (48.9) 15 (62.5) 0.280
Cardiovascular manifestations 17 (24.6) 9 (20.0) 8 (33.3) 0.221
Gastrointestinal manifestations 3 (4.3) 2 (4.4) 1 (4.2) 1.000
Renal manifestations 53 (76.8) 35 (77.8) 18 (75.0) 0.795
Nervous systemic manifestations 15 (21.7) 14 (31.1) 1 (4.2) 0.013
AAV-specific indices
BVAS 14.0 (8.0) 12.0 (7.5) 15.5 (9.0) 0.468
FFS 1.0 (1.0) 1.0 (1.5) 1.0 (1.0) 0.707
Acute phase reactants
ESR (mm/hr) 76.0 (80.5) 74.0 (84.0) 77.5 (88.3) 0.437
CRP (mg/L) 19.1 (69.4) 21.0 (69.2) 16.5 (81.6) 0.786
Comorbidities
CKD (stage 3–5) 30 (43.5) 21 (46.7) 9 (37.5) 0.464
DM 19 (27.5) 14 (31.1) 5 (20.8) 0.363
HTN 24 (34.8) 15 (33.3) 9 (37.5) 0.729
Dyslipidemia 13 (18.8) 6 (13.3) 7 (29.2) 0.109
During the follow-up period
Poor outcomes and follow-up periods
All-cause mortality 11 (15.9) 8 (17.8) 3 (12.5) 0.736
Follow-up period based on all-cause mortality (months) 32.9 (55.3) 19.8 (39.5) 60.8 (61.8) 0.003
Relapse 29 (42.0) 14 (31.1) 15 (62.5) 0.012
Follow-up period based on relapse (months) 16.4 (34.5) 14.0 (34.1) 29.3 (38.6) 0.409
ESRD 18 (26.1) 7 (15.6) 11 (45.8) 0.006
Follow-up period based on ESRD (months) 19.8 (41.7) 17.0 (32.5) 33.1 (78.1) 0.279
CVA 7 (10.1) 4 (8.9) 3 (12.5) 0.687
Follow-up period based on CVA (months) 28.8 (45.6) 17.1 (38.6) 37.8 (50.7) 0.061
CVD 5 (7.2) 4 (8.9) 1 (4.2) 0.652
Follow-up period based on CVD (months) 32.0 (46.4) 19.8 (40.9) 43.4 (57.1) 0.006
MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; AZA, azathioprine; MMF, mycophenolate mofetil; AAV, ANCA-associated vasculitis; 
ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculitis activity 
score; FFS, five-factor score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hyperten-
sion; ESRD: end-stage renal disease; CVA, cerebrovascular accident; CVD, cardiovascular disease.
Values are expressed as medians (interquartile range) or n (%). 
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Comparison of cumulative relapse-free and 
ESRD-free survival rates among patients taking AZA 
only, MMF only, and MMF after AZA
No significant differences in cumulative relapse-free survival 
rates were observed not only between patients taking AZA only 
and those taking MMF only, but also between those taking 
AZA only and those taking MMF after AZA. Furthermore, cu-
mulative relapse-free survival rates between patients taking 
MMF only and those taking MMF after AZA also did not differ. 
However, regarding ESRD, patients taking MMF only exhibited 
a significantly lower cumulative ESRD-free survival rate than 
patients taking AZA only (p=0.028). No significant differenc-
es in the cumulative ESRD-free survival rates were observed 
among the other groups (Fig. 3). 
Cox hazard model analyses
To evaluate the independent predictive value of each variable 
at diagnosis for the occurrence of ESRD during follow-up, Cox 
hazards model analysis was conducted. In univariate analysis, 
smoking history (HR 0.611) decreased the occurrence of ESRD, 
whereas BVAS (HR 1.079) and HTN (HR 2.728) increased the 
occurrence of ESRD. However, renal manifestation and CKD 
(stage 3–5) at diagnosis were not significantly associated with 
the occurrence of ESRD during follow-up. In multivariate anal-
ysis, both BVAS [HR 1.087, 95% confidence interval (CI) 1.018, 
1.161] and HTN (HR 3.201, 95% CI 1.186, 8.638) independent-
ly increased the occurrence of ESRD during follow-up (Table 
2). In contrast, the addition of the variable of MMF only to the 
Cox hazards model analysis showed that MMF only increased 
the occurrence of ESRD over AZA only (HR 1.835) in univari-
able analysis. In multivariable analysis, including smoking his-
tory, BVAS, HTN, and MMF only over AZA only, both BVAS (HR 
1.172, 95% CI 1.068, 1.285) and MMF only over AZA only (HR 
4.823, 95% CI 1.338, 17.384) could independently predict the 
occurrence of ESRD (Table 2).
Comparison of cumulative ESRD-free survival rates 
between the higher and lower BVAS groups
Among patients with MPA and GPA with higher BVAS at diag-
nosis, those taking MMF only exhibited a significantly lower 
cumulative ESRD-free survival rate than patients taking AZA 
only (p=0.047). However, among patients with MPA and GPA 
with a lower BVAS at diagnosis, the cumulative ESRD-free sur-
vival rates did not differ between the two groups (p=0.683) 
(Fig. 4). Combined, these results indicated that in remission 
maintenance therapy for MPA and GPA, MMF only could be as 
effective as AZA for preventing the occurrence of ESRD in pa-
tients with the lowest tertile of BVAS at diagnosis.
Fig. 2. Comparison of cumulative poor outcome-free survival rates. Patients taking MMF only or MMF after AZA tended to show lower cumulative re-
lapse-free (p=0.117) and ESRD-free (p=0.059) rates during follow-up, compared to those in patients taking AZA only. However, they did not reach sta-
tistical significance. The numbers below are the number of patients followed at each period (0, 50, 100, 150 months). MMF, mycophenolate mofetil; 
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DISCUSSION
This study investigated the preventive potential of MMF against 
the occurrence of poor outcomes during follow-up in Korean 
patients with MPA and GPA and compared it with that of AZA. 
There were three important findings. First, cross-sectional com-
Fig. 3. Comparison of cumulative relapse-free and ESRD-free survival rates. Among patients taking AZA only, MMF only, and MMF after AZA, only pa-
tients taking MMF only exhibited a significantly lower cumulative ESRD-free survival rate than patients taking AZA only. The numbers below are the 
number of patients followed at each period (0, 50, 100, 150 months). ESRD, end-stage renal disease; AZA, azathioprine; MMF, mycophenolate mofetil. 
Table 2. Cox Hazards Model Analysis of Variables at Diagnosis for the Occurrence of ESRD during Follow-Up in Patients with MPA and GPA
Variables
Univariable Multivariable (without MMF only) Multivariable (with MMF only)
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age (yr) 0.994 0.964, 1.026 0.726
Male sex 0.727 0.258, 2.051 0.546
Body mass index 0.928 0.782, 1.100 0.388
Smoking history 0.611 0.000, 6500.122 0.046 0.000 0.000, 0.000 0.984 0.000 0.000, 0.000 0.989
MPO-ANCA (or P-ANCA) positivity 1.719 0.496, 5.956 0.393
PR3-ANCA (or C-ANCA) positivity 0.819 0.187, 3.583 0.791
Renal manifestation 2.354 0.654, 8.471 0.190
BVAS 1.079 1.014, 1.147 0.016 1.087 1.018, 1.161 0.012 1.172 1.068, 1.285 0.001
FFS 1.588 0.971, 2.598 0.066
ESR 1.005 0.994, 1.017 0.387
CRP 1.002 0.995, 1.009 0.584
CKD (stage 3–5) 0.880 0.344, 2.254 0.790
DM 1.569 0.606, 4.063 0.354
HTN 2.728 1.060, 7.020 0.037 3.201 1.186, 8.638 0.022 1.778 0.547, 5.778 0.338
Dyslipidemia 1.492 0.528, 4.220 0.450
MMF only over AZA only 1.835 1.032, 3.264 0.039 4.823 1.338, 17.384 0.016
ESRD, end-stage renal disease; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; MMF, mycophenolate mofetil; HR, hazard ratio; CI, confi-
dence interval; MPO, myeloperoxidase; ANCA: antineutrophil cytoplasmic antibody; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculi-
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parative analysis of the frequency of poor outcomes showed 
that patients taking MMF exhibited significantly higher fre-
quencies of relapse and ESRD occurrence than those taking 
AZA during follow-up. Second, comparative analysis consid-
ering the follow-up period revealed that patients taking MMF 
only exhibited a significantly lower cumulative ESRD-free sur-
vival rate than patients taking AZA only. Third, in terms of ESRD 
occurrence, among patients with MPA and GPA with higher 
BVAS at diagnosis, patients taking MMF only exhibited a signifi-
cantly lower cumulative ESRD-free survival rate than those tak-
ing AZA only, whereas among patients with MPA and GPA with 
the lowest tertile of BVAS at diagnosis, the cumulative ESRD-
free survival rates did not differ between the two groups. 
In Cox hazards model analysis, renal involvement of MPA 
and GPA at diagnosis was not significantly associated with the 
occurrence of ESRD. Therefore, the effect of the use of MMF 
and AZA on the occurrence of ESRD was investigated after ex-
cluding the effect of kidney involvement by selecting patients 
with renal manifestation at diagnosis. In 53 patients with renal 
manifestation at diagnosis, those taking MMF only showed a 
lower cumulative ESRD-free survival rate than those taking 
AZA only (p=0.025), which was similar to the results in all 
study population. However, the survival rates did not differ sig-
nificantly between patients taking MMF after AZA and those 
taking AZA only or between patients taking MMF only and 
those with MMF after AZA (Supplementary Fig. 1, only on-
line). This suggests that drug selection for remission mainte-
nance therapy was more important with respect to the occur-
rence of ESRD than renal manifestation at diagnosis.
Unexpectedly, in our data, underlying CKD did not increase 
the risk of ESRD occurrence. Since we defined underlying CKD 
as the patient being diagnosed with CKD prior to AAV diag-
nosis, the initial eGFR of patients with CKD was 41.2, which 
was not different from eGFR 62.0 for patients without CKD (p= 
0.289). It is thought that the reason the eGFR showed no differ-
ence was that patients without underlying CKD had decreased 
initial kidney function due to renal involvement of AAV.
Comparative analysis between patients taking AZA and those 
taking MMF (MMF only plus MMF after AZA) showed statisti-
cally significant differences in several variables at diagnosis 
(Table 1). First, patients taking AZA were older than those taking 
MMF. The Cox hazards model revealed age as a significant risk 
factor for all-cause mortality (HR 1.096, 95% CI 1.026, 1.171), 
similar to that of a previous study in the general population.10 
Assuming that the age of patients taking MMF is comparable 
to that of those taking AZA, there might have been a significant 
difference in all-cause mortality between the two groups. Since 
age was not a risk factor for poor outcomes, other than all-cause 
mortality, particularly ESRD (Table 2), there was no need to ad-
just the results of this study for age. Second, patients taking 
AZA had higher BMI than those taking MMF (22.7 kg/m2 vs. 
21.2 kg/m2). Unlike age, BMI was not an initial risk factor for 
all-cause mortality (HR 1.108, 95% CI 0.890, 1.379). This result 
might be attributable to a U-shape hypothesis of all-cause mor-
tality along with BMI.11,12 BMI was not associated with other 
poor outcomes in this study. 
Third, among clinical manifestations based on BVAS items, 
nervous systemic manifestations were observed more frequent-
ly in patients taking AZA than in those taking MMF. These re-
sults might have clinical significance for two reasons. First, the 
severity of peripheral neuropathy and/or central nervous symp-
toms or the frequency of motor nerve involvement might have 
been higher in patients taking AZA than in patients taking 
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Fig. 4. Comparison of cumulative ESRD-free survival rates between the higher and lower BVAS groups. Among patients with higher BVAS at diagno-
sis, those taking MMF only exhibited a significantly lower cumulative ESRD-free survival rate than patients taking AZA only, whereas among patients 
with the lowest tertile of BVAS at diagnosis, the cumulative ESRD-free survival rates did not differ between the two groups. The numbers below are 
the number of patients followed at each period (0, 30, 60, 90 months). ESRD, end-stage renal disease; BVAS, irmingham vasculitis activity score; MMF, 
mycophenolate mofetil; AZA, azathioprine. 
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have occurred more often in patients taking AZA than in pa-
tients taking MMF.3,14 However, comparisons of the numbers of 
patients exhibiting other serious clinical manifestations be-
tween patients with and without nervous systemic manifesta-
tion showed no significant differences between the two groups. 
However, given that plasma exchange is recommended in cas-
es of life-threatening major organ involvement, we also com-
pared the numbers of patients who underwent plasma ex-
change between patients with and without nervous systemic 
manifestations3 and observed no differences.
The variable of “MMF only over AZA only” was included 
and analyzed in multivariable Cox hazards model analysis in 
Table 2. However, strictly speaking, this variable should not be 
included in multivariable Cox hazards model analysis, since 
the durations of MMF and AZA administration did not match 
the follow-up period based on the poor outcomes of MPA and 
GPA. Nevertheless, this analysis was performed because all 
patients received the same CYC infusion protocol and the tim-
ing of initiating AZA or MMF as a maintenance therapy after 
CYC administration was approximately the same.9 We also per-
formed this analysis to identify risk factors at the time of diag-
nosis that affected the choice between AZA and MMF and to 
compare the efficacies of AZA and MMF in remission mainte-
nance therapy according to the presence or absence of each risk 
factor. We found that BVAS at diagnosis, together with the vari-
able of “MMF only over AZA only” predicted the occurrence of 
ESRD during follow-up in patients with MPA and GPA (Table 2). 
Although several studies have favored and advocated the use 
of MMF in remission maintenance therapy,15,16 research results 
thus far have consistently reported that the effect of MMF in re-
mission maintenance therapy is inferior to that of AZA.8 Com-
pared to previous studies, our study investigated the progression 
to ESRD in patients with systemic clinical manifestations that 
were not confined to renal manifestation. In addition, our study 
also compared the efficacy of AZA and MMF in remission main-
tenance therapy for preventing the occurrence of ESRD regard-
less of renal manifestations at diagnosis. Finally, our results 
demonstrated that MMF is as effective as AZA in remission 
maintenance therapy for patients with the lowest tertile of BVAS 
at diagnosis among patients who need CYC for induction ther-
apy. We also provided a method to obtain the optimal cut-off 
of BVAS at diagnosis for selecting MMF as a remission mainte-
nance therapeutic regimen.
Our study has several limitations. Since this was a single-cen-
ter cohort study, the number of patients included in the study 
was not sufficient to maximize its reliability. However, as pa-
tients registered in a single institution, the consistency of the 
diagnostic criteria and treatment schedule was ensured, and 
the omission of data was minimized. 
Another limitation of our study is the likelihood of differenc-
es in underling vasculitis burden between patients receiving 
AZA and MMF and the possibility of selection bias owing to ret-
rospective study design. Furthermore, our results should be in-
terpreted with caution because the disease duration and status 
of diseases, such as relapse, were different for each patient and 
because there is the possibility of a difference in the cumulative 
doses of glucocorticoids between patients receiving AZA and 
those receiving MMF, which might have affected the poor out-
comes. Nevertheless, the strength of this study is that, to the 
best of our knowledge, this is the first pilot study investigating 
the efficacies of MMF and AZA in remission maintenance ther-
apy among patients with MPA and GPA with lower activity at 
diagnosis. Moreover, we believe that our study has broadened 
the choice of remission maintenance therapeutic regimens. 
In conclusion, as remission maintenance therapy after in-
duction therapy using CYC, the preventive potential of MMF 
against ESRD during follow-up, but not death, relapse, CVA or 
CVD, was lower than that of AZA or MMF after AZA in patients 
with MPA and GPA. However, among patients with the lowest 
tertile of BVAS at diagnosis, there was no difference in occur-
rence of ESRD between AZA and MMF, regardless of the initial 
renal manifestation. We believe that this study will serve as the 
basis for conducting further research on the efficacy of MMF 
as a maintenance therapy in patients with AAV with lower ac-
tivity.
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